38 results on '"Ribakovsky, Elena"'
Search Results
2. Supplementary Figure 3 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
3. Supplementary Figure 1 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
4. Supplementary Figure 2 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
5. Supplementary Figure 4 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
6. Supplementary Figure 5 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
7. Nivolumab Maintenance in First Complete Remission of Diffuse Large B-Cell Lymphoma
8. Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL
9. Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL.
10. Supplement to: Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
11. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
12. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients
13. Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol
14. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience
15. Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome
16. Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis
17. Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data
18. Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma
19. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
20. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
21. The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway
22. Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors
23. Mutations in STN1 cause Coats plus syndrome and are associated with genomic and telomere defects
24. Prognostic Value of Interim and End of Treatment FDG-PET/CT Scan Results in Adult Patients with Burkitt Lymphoma - a Retrospective Analysis of a Single Center Cohort
25. Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study
26. Infections Associated with Bendamustine – a Retrospective Multicenter Study
27. Essential Thrombocythemia Patients with CALR Mutations Have Increased Platelet Activation Markers Compared to JAK2V617F Mutated Patients
28. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-d-glucose–positron emission tomography/computed tomography in mantle cell lymphoma?
29. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients
30. Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
31. Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study.
32. CXCR4 Antagonist BKT140 Synergizes with Rituximab, Targeting Non Hodgkin Lymphoma (NHL) In Vitro and In Vivo in a Xenograft Model with Bone Marrow Involvement
33. Multiple Myeloma and Microenvironment Formation: The Role of CXCR4/CXCL12 Chemokine Pathway
34. Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation.
35. Transformation to Myelofibrosis and Blastic Transformation of PV Are Associated with Higher JAK2 Mutation Levels.
36. Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).
37. Treatment of Donor Graft Failure with Autologous or Allogenenic Stem-Cell Boost or a Second Allogeneic Transplant Based on Chimerism Testing.
38. Outcome Differences in Patients with Precursor B Cell Acute Lymphocytic Leukemia Over Time: A Retrospective Analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.